Genetic mutations among CRC patients, such as APC, BRAF, EGFR, KRAS and PIK3CA, could influence the response to specific therapies, such as anti-EGFR and immunotherapy [11,12,13,14]. This evidence concerns the gene EGFR and colorectal carcinoma.